|
Peter K. Kaiser, MD |
 |
Peter K. Kaiser, M.D. is staff surgeon on the vitreoretinal faculty of the Cole Eye Institute at the Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Kaiser graduated magna cum laude from both Harvard College and Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute.
As a National Institute of Health funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. In addition, Dr Kaiser is actively involved in clinical research as Study Chairman of 4 major, multi-center, international clinical trials, and principal investigator in over 20 trials for new treatments for AMD and DR and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR) which is the OCT coordinating center for over 25 clinical trials. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored four textbooks, and more than 150 book chapters and peer-reviewed papers. He is Editor-in-Chief of Current Concepts in Retina, Associate Editor of the American Journal of Ophthalmology and International Ophthalmology Clinics, Site Editor forthe WebMD/Medscape Ophthalmology site, and serves on the editorial boards of Retina, Retina Today, Retinal Physician, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Achievement and Senior Achievement Awards, and is listed as one of the “Best Doctors in America.” He is the team ophthalmologist for the Cleveland Browns (National Football League), Cleveland Cavaliers (National Basketball Association), and the Cleveland Indians (Major League Baseball). |
 |
Darius M. Moshfeghi, MD |
 |
Darius M. Moshfeghi, MD, is Co-Director of Ocular Oncology at Stanford University and leads the Pediatric Vitreoretinal Surgery service. His research interests have focused on the pathophysiology, diagnosis, and treatment of retinal and choroidal neovascularization, with a special focus on telemedicine for retinopathy of prematurity. He has been able to balance his academic interests with a successful and diverse consulting business.
Publications, Presentations, Academic Development
He has 58 PubMed Indexed publications, 14 other peer-reviewed publications, 18 book chapters, 58 Abstracts, and over 55 presentations internationally. He is serving as an editor of the book “Curbside Consultations in Retina” and has been invited to serve as chief editor of the 3rd edition of “Vitreoretinal Surgical Techniques.” Additionally, he is serving a three year term as a grant reviewer for Fight For Sight and recently accepted a three year position on the American Academy of Ophthalmology’s COMPASS Panel.
Industry-Sponsored Trials
Dr. Moshfeghi has served as the Principal Investigator for the Allergan RVO Posurdex trial and the Regeneron VIEW 1 VEGF trap trial, as well as a sub-investigator for the Genentech MARINA and ANCHOR trials, and the Novartis TAP trial.
Telemedicine
He is an internationally recognized authority on telemedicine for retinopathy of prematurity (ROP). In November 2005 he unveiled the Stanford University Network for Diagnosis of Retinopathy (SUNDROP) telemedicine outreach initiative. Presently, SUNDROP is the largest telemedicine network for ROP in the United States, with over 10,000 images having been evaluated in 2 ½ years. Analysis of the data has demonstrated that SUNDROP is a highly sensitive and specific technique for diagnosis and screening of ROP. He is presently collaborating with two groups in China and one group in Chile to aid in establishing ROP telemedicine screening networks. Additionally, he is developing a collaboration in Beijing to serve as a reading center for a study evaluating a new therapy for ROP.
Consulting and Therapeutic Development
In the past year, he has been working to develop new therapies for age-related macular degeneration with two separate companies, working on a patent and product roll-out for a surgical device company, and serving on the Scientific Advisory Board of Clarity Medical Systems, Inc.
Legal Consulting
Dr. Moshfeghi serves as an expert witness in selected cases and is sought after for expertise in complications of intravitreal injections and in ROP.
Internet
Most recently, he has served as Head of the Ophthalmology section and Editor of the Retina Section for www.ophthalmologyweb.com. As part of his duties, he recruited the Editors of Cornea, Glaucoma, Refractive, and two associate Retina editors. According to the website’s media kit, over 65,000 visitors per month have visited the site since its launch in October 2007.
|
|
Kang Zhang, MD, PhD |
 |
Kang Zhang, MD, PhD
was born in Sichuan, China and obtained his M.D. with Magna Cum Laude honors from Health and Science Technology program of Harvard Medical School and MIT joint MD program and his PhD in genetics from Harvard University. He completed his residency in ophthalmology at Wilmer Eye Institute at Johns Hopkins University and his retina fellowship at University of Utah. He was a faculty at Johns Hopkins University from 1999-2000, Cleveland Clinic Foundation from 2000-2002. He has been on faculty at University of Utah since 2002. He is currently Director of Ophthalmic Genetics and co-Director of International Ophthalmology of Moran Eye Center and Associate Professor of Ophthalmology and Visual Science. Among his honors include Burroughs Wellcome Fund Clinical Scientist Award in Translational Research; Lew R. Wasserman Merit Award from Research to Prevent Blindness; Macula Society membership; American Society of Clinical Investigation membership; Charles Schepens Award for Excellence in Retina Research; and Johns Hopkins Medical Institutions Clinician Scientist Award. His research focuses on novel disease gene targets and therapies in macular degeneration, diabetic retinopathy and inherited retinal degenerations. He has numerous grants from National Institute of Health, and other foundations and holds 3 patents. Dr. Zhang has published or co-authored more than 70 peer reviewed manuscripts in top journals including Science, New England Journal of Medicine, Nature, Nature Genetics, Nature Medicine, Cell, PNAS -- covering topics in genetics, molecular biology, and clinical trials in ophthalmology.
|
|
Jonathan Prenner, MD |
 |
A native of Long Island, Dr. Jonathan L. Prenner received his BA from the University of Pennsylvania, and then attended medical school at the State University of New York, Stony Brook. He was accepted into the Alpha Omega Alpha Honor Society and served as its president at the State University of New York, Stony Brook. He was also president of the student chapter of the American Medical Association at SUNY. Following his internship at Long Island Jewish Medical Center, Dr. Prenner returned to the University of Pennsylvania's Scheie Eye Institute for residency training in ophthalmology, and served as chief resident. He performed his fellowship in vitreoretinal disease at William Beaumont Hospital in Royal Oak Michigan, one of the premier retina training programs in the country. He was honored with a Ronald G. Michels Foundation Fellowship, and a Heed Foundation Fellowship.
Dr. Prenner is board-certified by the American Board of Ophthalmology, and is a member of the Society of Pediatric Retinal Surgeons, American Academy of Ophthalmology, American Society of Retinal Specialists, Association for Research in Vision and Ophthalmology, American Medical Association, the New Jersey Retina Society and Alpha Omega Alpha. He serves on the staff of UMDNJ-Robert Wood Johnson University Hospital in New Brunswick, NJ. He is also the president of the New Jersey Retina Society.
Dr. Prenner has published more than a dozen peer reviewed articles and has been invited to lecture nationally and internationally. He has a broad-based knowledge of retinal problems and particular excellence and surgical experience in advanced retinal detachment repair. He has also been involved in a host of clinical trials concerning retinal disorders.
|
|
Andrew A. Moshfeghi, MD |
 |
Andrew A. Moshfeghi, MD is the Medical Director of the Bascom Palmer Eye Institute at Palm Beach Gardens and is an Assistant Professor of Ophthalmology at the Bascom Palmer Eye Institute in the Department of Ophthalmology at the University of Miami Miller School of Medicine. Additionally, Dr. Moshfeghi serves as the Medical Director of the Bascom Palmer Surgery Center at the University of Miami Miller School of Medicine.
In his capacity as Medical Director, Dr. Moshfeghi manages the clinical activities of nearly 90 employees at the Bascom Palmer Eye Institute at Palm Beach Gardens. The $25 million facility is located on a 7-acre site in Palm Beach County, Florida and is comprised of a 65,000 square foot clinical and surgical complex with 52 examination lanes, 8 full-time sub-specialty ophthalmologists, 15 visiting ophthalmologists, 3 post-graduate clinical fellows, 3 sub-specialty research groups, 3 ophthalmic ambulatory surgical center suites, a state-of-the art conference theater with telemedicine capabilities, and the most modern keratorefractive laser technology.
Education & Training
Dr. Moshfeghi received a Bachelor of Arts degree from the University of Chicago and a Doctor of Medicine degree from Tulane University School of Medicine. This was followed by a rotating Transitional Medicine Internship at MetroWest Medical Center/Harvard Medical School Program in Framingham, MA. He then completed his Ophthalmology Residency at North Shore University Hospital, a teaching affiliate of New York University School of Medicine.
Dr. Moshfeghi's three-year clinical fellowship training included both Medical Retina and Vitreoretinal Surgery fellowships at the Bascom Palmer Eye Institute in the Department of Ophthalmology at the University of Miami Miller School of Medicine in Miami, FL.
Clinical and Research Interests
In 2005, he was a recipient of the Ronald G. Michels Fellowship Foundation Award, which is granted annually to one or more outstanding senior vitreoretinal surgical fellows.
Dr. Moshfeghi is currently completing an Executive MBA program in Health Administration and Policy, for which he received a full-tuition academic scholarship at the University of Miami Graduate School of Business Administration.
Publications, Presentations, Academic Development
Dr. Moshfeghi is the author of 30 peer-reviewed articles, 7 book chapters, and 54 abstracts. He also serves as a scientific referee for 10 scientific publications as the Associate Retina Section Editor for OphthalmologyWeb. Along with Drs. Rosenfeld and Puliafito, he co-authored the first article describing the use of intravitreal bevacizumab (Avastin, Genentech, Inc.) in humans with neovascular age-related macular degeneration. He has delivered 17 invited lectures at various local, national, and international scientific symposia. Dr. Moshfeghi is a founding member of The CONNECT Network and the Vitrectomy-Buckle Society.
Clinical and Research Interests
Dr. Moshfeghi's clinical practice encompasses comprehensive surgical and non-surgical diseases of the retina, macula, and vitreous. His research interests include new treatment approaches for age-related macular degeneration and diabetic retinopathy as well as evaluation and development of novel intraocular pharmacotherapeutics and retinal imaging techniques. Dr. Moshfeghi has served as Principal Investigator on 5 clinical trials and as a co-investigator on 20 clinical trials.
Biotechnology and Health Care Consulting
Dr. Moshfeghi serves as a sought-after consultant to various pharmaceutical and ophthalmic medical device corporations. He frequently serves as an expert legal advisor.
|
|
John W. Kitchens, MD |
 |
John W. Kitchens, MD is a partner in Retina Associates of Kentucky. His focus is in the management of medical and surgical diseases of the retina.
Training
Dr. Kitchens graduated with honors from the Indiana University School of Medicine. He performed his residency in ophthalmology at the University of Iowa Department of Ophthalmology. Following his residency, he performed a retina fellowship at the Bascom Palmer Eye Institute. He then served as Chief Resident and the Direct of the Trauma Service at the Bascom Palmer Eye Institute.
Honors
Dr. Kitchens has received numerous honors. He has been named to the Best Doctors in AmericaTM. He was nominated for Resident of the Year in the state of Florida. Dr. Kitchens won first place in the national resident cataract surgery video competition sponsored by the American College of Eye Surgeons in 2003. He has been featured on the Discovery Channel’s Mystery Diagnosis and the Learning Channel’s Diagnosis X.
Research
Dr. Kitchens is involved as a investigator in multiple clinical trials for age-related macular degeneration (AMD), diabetic retinopathy, retinal vascular occlusive disease, and visual rehabilitation. His research includes papers and presentations on ocular imaging, ocular histolasmosis, AMD, innovations in surgical instrumentation, and various other topics. He has presented at various meetings including AAO, ARVO, ASRS, and Angiogenesis.
Consulting
He serves as consultant for Genentech, Optos, Novavision, and Allergan. In addition to this Dr. Kitchens serves as the Section Editor of Retina for Ophthalmology Web (www.ophthalmologyweb.com).
|
|
Richard S. Kaiser, MD |
 |
Dr. Richard Kaiser received his undergraduate degree from the University of Pennsylvania and his medical doctor degree from New York University School of Medicine, where he was awarded recognition for his ophthalmic research. He completed his medical internship at Presbyterian Hospital/University of Pennsylvania. Dr. Kaiser performed his ophthalmology residency at the University of Pennsylvania and Scheie Eye Institute where he was appointed Chief Resident. Dr. Kaiser completed his two-year vitreoretinal fellowship at William Beaumont Hospital, Royal Oak, Michigan where he was awarded two national honors, the Heed Ophthalmic Fellowship Award and the Ronald G. Michels Retinal Fellowship Award. Following his formal training, Dr. Kaiser was in private practice as a vitreoretinal surgeon at Wills Eye Hospital and other suburban Philadelphia areas for several years. He joined Retinovitreous Associates in July, 2004. Dr. Kaiser is on staff at Wills Eye Hospital and currently serves as Compliance Officer of the Wills Retina Service. He is an instructor at Jefferson Medical School of Thomas Jefferson University Hospital. Additionally, he is on the active medical staff at Holy Redeemer Hospital, Huntingdon Valley, PA and Abington Hospital, Abinton, PA. He also serves on the surgical board for Holy Redeemer Hospital. Dr. Kaiser is Board Certified in Ophthalmology. He is a member of the American Academy of Ophthalmology, the American Society of Retina Specialists, the Society of Heed Fellows, the Philadelphia Inter-County Ophthalmic Society, Pennsylvania Medical Society, Club Vitreous and the Ophthalmic Club of Philadelphia, currently serving as its Secretary/Treasurer. He serves as Manuscript Referee for Ophthalmology, the Journal of the American Academy of Ophthalmology and Retina, The Journal of Retinal and Vitreous Diseases. Dr. Kaiser is the Principal Investigator at Wills Eye Hospital for clinical trials evaluating new treatments for age-related macular degeneration, and macular edema in CRVO. He has authored numerous publications on vitreoretinal diseases, and has been an invited speaker to present scientific papers at both national and international meetings. He maintains special interests in adult retinopathy of prematurity, diabetic retinopathy and its complications, and age-related wet macular degeneration.
|
|
|
 |
|
|
|
